Infectious Disease, Respirology
Optimizing RSV Protection for All Infants
This is a 60-minute eCME for Canadian HCPs. Due to the significant burden of disease of RSV in infants and young children, the goal is to provide education on the role of RSV immunoprophylaxis in disease prevention. This program is designed to provide practical information on recently authorized RSV immunoprophylaxis available in Canada, with a focus on nirsevimab, a long-acting monoclonal antibody. Utilizing case studies and expert videos, the program will review the burden of RSV disease in infants, supporting evidence for recently approved RSV immunoprophylaxis, NACI guidance for RSV immunoprophylaxis for all infants and considerations for the use of nirsevimab in clinical practice.
DURATION
1 hr
PROFESSION
Physician, Nursing, Pharmacy, Allied Health, Medical Resident, Student, Specialist
# OF CREDITS
0
ACCREDITATION
Unaccredited
EXPIRY DATE
2025-08-12
Respiratory syncytial virus (RSV) is one of the most common respiratory viruses in infants and young children, infecting almost all children by two years of age. RSV accounts for a significant burden of disease in infants and young children, causing serious complications for infants, including hospitalization, as well as significant impact on caregivers and families. Although the risk of severe RSV disease is higher in infants with certain medical conditions including prematurity, full-term infants account for the highest proportion of infants with severe RSV disease. In order to address this substantial disease burden, NACI has recently issued new guidance for RSV immunoprophylaxis for all infants with a focus on the use of nirsevimab to prevent severe RSV disease. In 2023, Health Canada authorized two new RSV immunoprophylaxis: nirsevimab, a long-acting monoclonal antibody, and RSVpreF, a maternal vaccine. NACI guidelines state that nirsevimab is currently preferred over RSVpreF due to its higher efficacy and possible longer duration of protection.
This program has received an unrestricted educational grant or in-kind support from Sanofi.
Faculty
- Marc Lebel, MD, FRCPC
- Christine Palmay, HBArtSci, MD, CCFP, FCFP
- Erin Fleischer, RN (EC) NP Paeds, BSCN, MN, ACNP
- Ronik Kanani, MD
Learning objectives
Upon completion of this continuing education program participants will be better able to:
- Cite the prevalence and burden of RSV disease in infants
- Evaluate clinical and safety data of recently approved RSV immunoprophylaxis for infants
- Summarize NACI guidance on RSV immunoprophylaxis for all infants
- Implement RSV immunoprophylaxis for infants in clinical practice
Accreditation
This program is unaccredited.
#
of credits: 0
Duration: 1 hr
FAQs & HELP
MDBriefCase Group specializes in accredited, online continuing professional development (CPD) programs, custom tailored for specific international markets and available on a convenient online platform.
All content is developed by leading specialists and peer-reviewed by experts at respected institutions, which keeps more than 280,000 global healthcare professionals at the forefront of the latest evidence and protocols worldwide.
The vast majority of our programs are accredited by one or more respected institutions. We do provide unaccredited content to ensure that healthcare professionals have access to relevant practical resources in addition to accredited learning.
Specific accrediting information (including the accrediting body, along with the type and number of credits) can be found on the “Main” page and/or “Accreditation” page of each program. In order to qualify for accreditation and obtain your certificate, you must successfully complete the requirements listed on the “Accreditation” or “CME Information” pages available in each program.
MDBriefCase Group works with various institutions to provide peer-reviewed, up-to-date accredited content. Our programs and resources are provided via collaboration between medical writers, faculty members, associations, universities and other relevant organizations. The content you were recommended is likely valued by your society or association and is conveniently provided to you free of charge on an MDBriefCase Group platform.
Specific accrediting information (including the accrediting body, along with the type and number of credits) can be found on the “Main” page and/or “Accreditation” page of each program. In order to qualify for accreditation and obtain your certificate, you must successfully complete the requirements listed on the “Accreditation” or “CME Information” pages available in each program.
If you are interested in learning more about supporting one of our programs, please contact us.
If you are interested in working with MDBriefCase Group as a writer or committee member, please contact us.
To access the MDBriefCase Group privacy policy, please click here.
No, registration with MDBriefCase is free!
To access your profile, visit My Profile. If you would like to update the information here don’t forget to hit the ‘save’ button when you are finished. Your profile is where you can control what email communications you receive.
If you have forgotten your password, you can reset your password. To access this page from the Login page, click Forgot password. Enter the email address you registered with and you will receive an email with a link to reset your password.
Please note: if you submitted multiple password resets, only the link on the most recent email is valid.
You can unsubscribe from MDBriefCase Group emails by clicking the unsubscribe button located at the bottom of each of our emails.
1 hr
Duration
Physician, Nursing, Pharmacy, Allied Health, Medical Resident, Student, Specialist
Profession
0
# of credits
Learning Objectives
Upon completion of this continuing education program participants will be better able to:
- Cite the prevalence and burden of RSV disease in infants
- Evaluate clinical and safety data of recently approved RSV immunoprophylaxis for infants
- Summarize NACI guidance on RSV immunoprophylaxis for all infants
- Implement RSV immunoprophylaxis for infants in clinical practice
Unaccredited
ACCREDITATION
Infectious Disease, Respirology
Learning Category
Respiratory, Infectious Disease
Topic
0
Price
2025-08-12
Expiry Date
CAN-eng
Region/Language
Course Description
Respiratory syncytial virus (RSV) is one of the most common respiratory viruses in infants and young children, infecting almost all children by two years of age. RSV accounts for a significant burden of disease in infants and young children, causing serious complications for infants, including hospitalization, as well as significant impact on caregivers and families. Although the risk of severe RSV disease is higher in infants with certain medical conditions including prematurity, full-term infants account for the highest proportion of infants with severe RSV disease. In order to address this substantial disease burden, NACI has recently issued new guidance for RSV immunoprophylaxis for all infants with a focus on the use of nirsevimab to prevent severe RSV disease. In 2023, Health Canada authorized two new RSV immunoprophylaxis: nirsevimab, a long-acting monoclonal antibody, and RSVpreF, a maternal vaccine. NACI guidelines state that nirsevimab is currently preferred over RSVpreF due to its higher efficacy and possible longer duration of protection.
This program has received an unrestricted educational grant or in-kind support from Sanofi.
Faculty
- Marc Lebel, MD, FRCPC
- Christine Palmay, HBArtSci, MD, CCFP, FCFP
- Erin Fleischer, RN (EC) NP Paeds, BSCN, MN, ACNP
- Ronik Kanani, MD
Accreditation
This program is unaccredited.
1 hr
Duration
0
Price
0
# of credits
